Awakn Life Sciences will attend upcoming conferences in May 2022

Toronto, Ontario–(Newsfile Corp. – May 5, 2022) – Awakn Life Sciences Corp. AWKN AWKNF (FSE: 954) (“Awakn”), a biotechnology company that researches, develops and delivers combination therapies to treat addiction, today announced that Awakn’s management team is scheduled to present at the following conferences in May 2022.

PSYCH Symposium: London 2022

  • Date: Wednesday, May 11, 2022
  • Location: The National Gallery in London, UK
  • Presentations:
    • Professor David Nutt, Director of Research, will present “Between Receptor and Mind: How Psychedelics Work in the Brain” at 10:40 a.m. BST.
    • Professor Celia Morgan, Head of Ketamine Assisted Therapy, and Professor Nutt will participate in the panel “The Importance of Industry Sustainability – A Patient-Centered Approach” at 4:30 p.m. BST.
  • Assist: register here

Nordic Conference on Psychedelic Science

  • Date: May 19-20, 2022
  • Location: Oslo, Norway
  • Presentation:
    • Teacher Celia Morgan, Head of Ketamine Assisted Therapy, will present “Ketamine Assisted Therapy for Drug Addiction“Thursday, May 19and at 2:30 p.m. CET.
    • Dr. Ben Sessa will present “Exploring MDMA for Addictions” on Friday, May 20and at the evening Symposium.
  • Assist: register here

HC Wainwright Global Investment Conference

  • Date: May 23 – 26, 2022
  • Location: Virtual
  • Presentation: A Fireside Chat with Anthony Tennyson, CEO, will be available on demand from Tuesday, May 24and at 7:00 a.m. ET.
  • Assist: register here

From Research to Reality: World Summit Conference on Psychedelic-Assisted Therapies and Medicine

  • Date: May 27 – 29, 2022
  • Location: Hilton Toronto Downtown in Toronto, Canada
  • Presentation:
    • Professor David Nutt, Awakn’s Director of Research, will present on the panel “Historical and recent advances in psychedelic science, neuroscience, and clinical contributions to substance use and addiction“Friday, May 27and at 8:45 a.m. ET.
    • Dr. Ben Sessa, Chief Medical Officer of Awakn, will present on the panel “Policy, Public Health and Regulatory Issues: Setting the Research Agenda for Psychedelic-Assisted Therapies for Substance Use Disorders“Friday, May 27and at 5:30 p.m. ET.
    • Professor David Nutt, Awakn’s Director of Research, will present on the panel “Psychedelic-Assisted Therapy – Fact and Fiction featuring some of the world’s top researchers in the field of Psychedelic-Assisted Therapies and Medicine“Saturday, May 28and at 7:30 p.m. ET.
  • Assist: register here

For more information about each conference or to schedule a one-on-one meeting with the Awakn leadership team, please contact your appropriate representatives or email KCSA Strategic Communications at [email protected]

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company that researches, develops and delivers combination therapies to treat addiction, with a focus on alcohol use disorders. Awakn’s team is made up of world renowned research experts, chemists, scientists, psychiatrists and psychologists. Drug addiction is one of the greatest unmet medical needs of our time, affecting over 20% of the world’s population and is an industry valued at over $100 billion a year. Awakn is disrupting this underperforming industry by rapidly advancing the next generation of drugs and therapies for use in combination, through preclinical research and clinical trials.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Investor requests:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media inquiries:
America and Canada: KCSA Strategic Communications
Anne Donohe
[email protected]

Rest of the world: ROAD Communications
Paul Jarman/Nora Popova
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122827

Comments are closed.